Search Results

Nora Pharma, a Canadian pharmaceutical company, has received approval for its first Biosimilar product.

Sunshine Biopharma Inc. is happy to announce that its wholly owned generic pharmaceutical subsidiary, Nora Pharma, has received approval for its first Biosimilar product.

As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives find themselves faced with policy questions ranging from the Inflation Reduction Act to RFK Jr.

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved into a new pharma stratosphere, far eclipsing their rivals.

China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.

COUR Pharmaceuticals has been around a while, but not until last year did the company solidify behind its ultimate mission with a series A raise.

Sunshine Biopharma Inc. today announced that it has completed the acquisition of all the outstanding shares of Nora Pharma Inc., effective immediately.

Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.

Zai Lab Limited announced that the final overall survival data from the Phase 3 randomized, double-blind, placebo-controlled NORA study evaluating ZEJULA® in Chinese patients with platinum-sensitive recurrent ovarian cancer will be shared in oral presentations at the 2024 Congress of the European Society of Gynaecological Oncology and the 2024 Society for Gynecologic Oncology Annual Meeting on Women’s Cancer.

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share price. Other companies have not been so lucky.